"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose Escalation And Proof-Of-Concept Study To Evaluate The Safety And Efficacy Of Razuprotafib In Hospitalized Subjects With Moderate To Severe Coronavirus Disease 2019
Posted Date: Oct 2, 2020
- Investigator: Richard Becker
- Specialties: Pulmonary Diseases, Vascular
- Type of Study: Drug
Patients with COVID-19 have vascular inflammation and impaired capacity to restore vascular health. This leads to blood clotting and vital organ damage. A targeted approach to protecting blood vessels from virus-associated injury could have marked benefit. The primary objectives of this study are to assess the safety and efficacy of razuprotafib in subjects with moderate to severe COVID-19. The secondary objectives of this study are to examine the effects of razuprotafib on biomarkers of inflammation and coagulopathy (ie, C-reactive protein [CRP] and D-dimer) in the plasma of subjects with moderate to severe COVID-19 and to characterize exposure of razuprotafib based on plasma concentrations for the samples collected on Day 1 and Day 6. The exploratory objective of this study is to examine the effects of razuprotafib on biomarkers of vascular leakage and inflammation (ie, angiopoietin [Angpt]-2, interleukin [IL]-6, IL-8, tumor necrosis factor alpha [TNFa], and high mobility group box 1 [HMGB-1]) in the plasma of subjects with moderate to severe COVID-19.
Criteria:
Patients With Moderate-To-Severe Covid-19
Keywords:
Covid-19, Blood Vessel Repair, Vascular Health
For More Information:
Richard C. Becker, Md
5135584332
richard.becker@uc.edu